Skip to main content

Table 1 Patients characteristics

From: Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Characteristics Number of patients Percentage
Age   
≤ 60 12 38.7
> 60 19 61.3
Gender   
Male 23 74.2
Female 8 25.8
ECOG PS   
0-1 27 87.1
2-4 4 12.9
B symptom   
Absent 14 48.3
Present 15 51.7
Bulky disease   
Absent 21 67.7
Present 10 32.3
LDH   
Normal 4 12.9
Elevated 27 87.1
Primary site of adrenal gland   
Unilateral 12 38.7
Bilateral 19 61.3
Adrenal insufficiency   
Absent 10 62.5
Present 6 37.5
Ann Arbor stage   
IE, IIE 5 16.1
IIIE, IV 26 83.9
Number of extranodal sites   
0-1 7 22.6
2 or more 24 77.4
Ki-67 LI   
> 80% 11 57.9
≤ 80% 8 42.1
IPI   
Low/Low-intermediate 8 25.8
High-intermediate/High 23 74.2
  1. ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; Ki-67 LI, Ki-67 labeling Index; IPI, International Prognostic Index.